BioDuro-Sundia Expands Drug Discovery Capacity and Capability

SHANGHAI--(BUSINESS WIRE)--BioDuro-Sundia has recently completed Discovery capability expansions of more than 100K ft² of laboratory space within three different R&D Centers (Shanghai Waigaoqiao, Shanghai Zhangjiang, and Beijing).

Dr. Xiang Li, President of BioDuro-Sundia Drug Discovery, explains: “At BioDuro-Sundia, we are fully invested in our clientele and pro-actively planning ahead to meet their needs. A few highlights of this expansion include:

• Discovery Biology department:
  • Enlarged HCS capability
  • Developed more than 180 new biochemical and cell assays
• Pharmacology department added 15+ new disease models
• Oncology department:
  • Added 40+ CDX models
  • Increased IVIS based real-time metastasis and drug distribution analyses
• Biologics department initiated a VHH library based on:
  • Alpaca immunity, ADC, high-throughput antibody expression, affinity detection and physical and chemical characterization services
• DMPK department added many in-vivo and in-vitro detection services.

All together, we substantially enhanced our capabilities and capacity to provide better services to our customers. We’re committed to offering both our pharma and biotech partners worldwide advanced, high-quality technical solutions for new drug discovery.”

Dr. Kent Payne, BioDuro-Sundia’s CEO, stated: “Our Discovery Team has advanced countless candidate compounds to the clinic around the world. These new expansions position us for continued growth as part of our commitment to accelerate client projects to the clinic.”

BioDuro-Sundia’s Drug Discovery platform provides end-to-end services from hit identification to lead optimization and candidate selection/profiling. Some notable technology platforms developed at BioDuro-Sundia include PROTAC, Fragment-based drug discovery (FBDD), DNA-encoded library (DEL), Nanobody, NASH models etc.

About BioDuro-Sundia

BioDuro-Sundia, an Advent International portfolio company, is a trusted, leading contract research development, and manufacturing organization (CRDMO) for over 27 years. We provide our biotech and pharmaceutical partners with fully integrated services to support their efforts from target identification through to commercial drug product manufacturing. The company is based in the US and China with more than 3,000 employees and 10 global sites across 7 cities.

Core expertise includes small and large molecule discovery, development and scale up, support for IND submission, and unique technology platforms such as bioavailability enhancement of insoluble compounds. The one-stop-shop operation helps biotech and pharma partners across the globe to significantly accelerate discovery and de-risk development to create higher value outcomes. We adhere to one global highest standard of compliance and business operation code. Our science-driven, customer-oriented, people-focused culture enables us to provide top-tier integrated, fast, and flexible tailored services to our customers, to meet their unique needs and accelerate development timelines. For more information, please visit www.bioduro-sundia.com.

Christina Coby
christina.coby@bioduro-sundia.com